Subsequent clinical trials are currently investigating sotorasib as monotherapy or in combination with various anticancer agents in patients with advanced or metastatic solid tumors, including NSCLC and CRC, with the KRAS p.G12C mutation (Table 1). Here, KRAS is linked to non-small cell lung carcinoma.